A Study of Replagal in Treatment-naïve Adults With Fabry Disease
Status:
Not yet recruiting
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
In this study, adults with Fabry Disease who have not had any treatment for this condition
will be treated with Replagal. The main aim of the study is to check if Replagal improves
kidney function and heart structure of participants with Fabry Disease. Participants will
receive one Replagal infusion every other week for up to 104 weeks. They will visit the
clinic every 12 to 14 weeks during treatment with a follow-up visit 2 weeks after treatment.